High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
One company is generating substantial free cash flow and returning billions to shareholders. The other is still working toward its first profitable year. The risk profiles could not be more different.
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Here is a way to collect a steady income stream from Adobe stock right now, which you keep no matter what, while lining up a chance to buy this creative software giant at a deep discount if its turnaround stumbles.
One company is a profitable, growing leader in cybersecurity. The other is an early-stage quantum computing bet with enormous long-term potential but a long road ahead.
The drugmaker should significantly mitigate its most important risk as it develops new products.
Arista commands networking with zero debt and 39% margins, while AppLovin's AI platform grew 70% with a lower valuation, but each carries distinct risks.
One operates a restructuring retail network with negative free cash flow; the other burns cash on pre-revenue aviation tech backed by Toyota and Delta.
According to Intel’s latest filings with the Securities and Exchange Commission (SEC), the company held a steady 15.3 million shares of Joby and 50 million Class A shares of Mobileye as of both March 31 and June 30.
A number of stocks jumped in the afternoon session after a wave of upbeat earnings reports and bullish forecasts from key industry players signaled robust and sustained demand for artificial intelligence technology.
PayPal Holdings is in talks to sell itself to a group that includes Stripe and the private-equity firm Advent International, according to people familiar with the matter. Stripe and Advent in July proposed paying $60.50 a share for PayPal, a price PayPal viewed as insufficient, some of the people said.
Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.
Gold surged after a bruising jobs report, but GLDM still sits well below its 2026 record, and that gap creates a very different conversation than buying bullion at a peak.
A number of stocks jumped in the afternoon session after a wave of upbeat earnings reports and bullish forecasts from key industry players signaled robust and sustained demand for artificial intelligence technology.
Trade barriers are supposed to be simple machines. You raise the price of a thing until buying it stops making sense, and the buying stops. Washington built one of the tallest of those walls in modern trade policy around Chinese electric vehicles, and by the only measure most people can see, it ...
One company is accelerating across every major division, while the other is managing a complicated restructuring.
Despite its plummeting share price in recent years, this stock has delivered annualized total returns of 16% since 2015.
West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.
Tesla's chief designer indicated that the repeatedly delayed electric sports car could finally be approaching its production-form debut.
AMD's four-part bond offering gives the chipmaker additional financial flexibility as it expands its artificial-intelligence infrastructure business.
Rising DRAM and NAND prices could amplify the earnings effect of Micron's rapidly expanding data-center demand.
Bristol Myers Squibb (BMY) is back in focus after the FDA granted accelerated approval for ZENBEXUS in a multiple myeloma combination regimen, introducing the first approved CELMoD therapy in this disease setting. See our latest analysis for Bristol-Myers Squibb. The ZENBEXUS approval lands at a time when Bristol-Myers Squibb’s momentum has picked up, with the share price at US$64.65 and a 30 day share price return of 13.52%. That builds on a 20.93% year to date share price return and a...
Red Cat stock soars as Trump announces aggressive tariffs on foreign drones. But Wall Street believes RCAT shares will rip higher through the remainder of 2026.
SanDisk, Pagaya, NeoVolta and Aeromexico offer 35%+ upside potential after strong Q2 results, with growth catalysts across key industries.
Unusual Machines stock soars as President Trump aggressively raises tariffs on foreign drones. But is it too late to invest in UMAC shares already?
Pershing Square believes Netflix's scale, advertising growth and expanding margins outweigh concerns about engagement and AI-generated content.
Almost every ETF claiming to own Dividend Aristocrats actually mixes in other holdings, but a small group of funds holds nothing but these elite dividend growers. Choosing the wrong one in 2026 could cost you years of compounding.
Can we count your visit with Google Analytics? No ads, no profiles. Details
